Evaluation of Mycophenolate Mofetil role as an immunomodulator in high risk keratoplasty patients | ||
| Egyptian Journal of Ophthalmology | ||
| Volume 5, Issue 3, September 2025, Pages 122-133 PDF (306.71 K) | ||
| Document Type: Original Articles | ||
| DOI: 10.21608/ejomos.2024.321628.1146 | ||
| Authors | ||
| Myada Mohamed Zayed* 1; Mohamad Hany Abdel Rahman2; Hatem El-Said El-Awady2; Amgad El Nokrashy2 | ||
| 1Mansoura University, Faculty of Medicine | ||
| 2Mansoura Ophthalmic Center, Mansoura University | ||
| Abstract | ||
| Objectives: This study is conducted to evaluate the role of Mycophenolate Mofetil in reduction of corneal graft rejection rates in high risk keratoplasty patients. Patients and Methods: Study includes 50 eyes scheduled for penetrating keratoplasty who met the inclusion criteria of high risk keratoplasty. Patients will be randomly divided into two groups; MMF group (25 patients) will receive MMF as an immunosuppressive drug pre and postoperative in addition to the topical steroid and antibiotic eye drops postoperative. Corticosteroid group (25 patients) will receive systemic corticosteroid pre and postoperative in addition to topical steroid and antibiotic eye drops postoperative. Results: Statistically significant differences were recorded in terms of BCVA after 1st week, 1st month, 3rd month, 6th month and one year of follow up in each group of studied groups. Statistically significant differences were documented according to complications of treatment after keratoplasty, state of corneal grafts and number of rejection episodes between studied groups (P<0.001). Conclusion: Mycophenolate Mofetil has a significant role in decreasing rates of corneal graft rejection after high risk penetrating keratoplasty. | ||
| Keywords | ||
| High risk penetrating keratoplasty; corneal graft rejection; Mycophenolate Mofetil | ||
|
Statistics Article View: 5 |
||
